Successful thrombolysis of a thrombosed prosthetic mitral valve using a synthetic tissue plasminogen activator: a case report by Al-Sarraf, Nael et al.
CASE REPORT Open Access
Successful thrombolysis of a thrombosed
prosthetic mitral valve using a synthetic tissue
plasminogen activator: a case report
Nael Al-Sarraf
1*, Fahad Al-Shammari
1, Jamal Al-Fadhli
1, Emad Al-Shawaf
2
Abstract
Introduction: Prosthetic valve thrombosis is a rare but life-threatening condition that requires careful evaluation
and prompt treatment. While surgical intervention remains the gold standard, thrombolytic therapy is now
emerging as a potential substitute. Various thrombolytic treatments including streptokinase, urokinase and
recombinant tissue plasminogen activators have been reported with variable success rates. However, the data on
the use of tenecteplase (a synthetic tissue plasminogen activator) is limited.
Case presentation: A 44-year-old Middle Eastern man with a previously implanted prosthetic mitral valve
presented with exertional dyspnea and orthopnea. Investigations revealed a thrombosed prosthetic mitral valve.
Successful thrombolysis was achieved using tenecteplase which lead to the complete restoration of valve function
with no risk to the patient.
Conclusion: Prosthetic valve thrombosis is a rare but life threatening condition, the diagnosis of which requires a
high index of suspicion. Tenecteplase can be used successfully in the management of such cases. It has proved to
be useful with no extra risk to the patient.
Introduction
Prosthetic valves thrombosis (PVT) is defined as any
obstruction of the prosthesis by non-infective thrombo-
tic material. The diagnosis of PVT is made by a combi-
nation of clinical data (heart failure, absence of
prosthetic sounds, cardiogenic shock) and echocardio-
grapy. The traditional treatment for PVT is surgery with
either thrombectomy or replacement of the prosthesis.
In recent years, thrombolytic therapy has evolved as a
substitute to surgery. Various thrombolytic treatments
have been reported with variable success rates including
streptokinase, urokinase and recombinant tissue plasmi-
nogen activators. However, the data on the use of tenec-
teplase (a synthetic tissue plasminogen activator) is
limited [1].
Case presentation
A 44-year-old Middle Eastern man was admitted for
mitral valve replacement. He had history of atrial
fibrillation and rheumatic heart disease affecting the
mitral valve (MV) with consequent severe mitral steno-
sis. He was a non-smoker and did not consume alcohol.
He had no family history of relevance. He weighed
60 kg and his height was 168 cm.
The patient underwent an uneventful mitral valve
replacement using a mechanical 29 mm St Jude prosthe-
sis. He was commenced on oral anticoagulant (warfarin)
and a beta blocker. His pre-discharge transthoracic
echocardiography (TTE) showed a well-functioning
prosthesis with no paravalvular leak. Six months later,
the patient presented to his local hospital with exer-
tional dyspnea and orthopnea. He admitted that he had
stopped taking his oral anticoagulant therapy 10 days
prior to hospitalization: his international normalized
ratio was 1.0.
His physical examination showed atrial fibrillation,
absent prosthetic click and congested lungs but was
otherwise unremarkable. Routine blood investigations
were normal. TTE showed immobile posterior mitral
leaflet and mobile anterior leaflet with a mean pressure
gradient of 20 mmHg (peak pressure 40 mmHg) and * Correspondence: trinityq8@hotmail.com
1Department of Cardiac Surgery, Chest Disease Hospital, Al-Jabriah, Kuwait
Al-Sarraf et al. Journal of Medical Case Reports 2010, 4:241
http://www.jmedicalcasereports.com/content/4/1/241 JOURNAL OF MEDICAL
CASE REPORTS
© 2010 Al-Sarraf et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.reduced surface area of 0.7 cm
2. He was then referred to
our center. His New York Heart Association class on
arrival was II and he was in a stable hemodynamic sta-
tus. A repeat TTE at our center showed a huge left
atrial (LA) thrombus in the posterolateral aspect of LA
involving the posterior cusp of MV prosthesis which
kept it in a closed position with a mobile anterior leaflet
(Figure 1A and 1B). These findings were confirmed by
transoesophageal echocardiography (TEE).
We proceeded with thrombolytic treatment using
tenecteplase (Boehringer Ingelheim, Germany) in a slow
intravenous infusion of 1.25 mg/h (dose was 0.5 mg/kg
and the patient body weight was 60 kg). The patient
was closely monitored in an intensive care unit for any
sign of cerebral embolism or bleeding. Thrombolysis
was continuous for 48 hours. Following 24 hours of
tenecteplase treatment, a repeat TTE showed recovery
of most of the MV mobility (Figure 2 Figure 2A and 2B)
w i t has i g n i f i c a n td e c r e a s ei nL At h r o m b u ss i z ea n da
recovering blood flow across the MV. The MV area was
2.7 cm
2 with no paravalvular leak and pericardial
effusion.
After 48 hours of treatment, a TEE showed well
functioning MV prosthesis with no residual thrombus
(Figure 2C and 2D). The surface area was 2.8 cm
2
and the peak pressure gradient across MV was
6 mmHg with a mean pressure gradient of 2 mmHg.
Following thrombolysis, intravenous anticoagulation
(unfractionated heparin) was started as a continuous
infusion together with oral anticoagulation therapy
(warfarin). The combination was then continued until
his International Normalised Rate was in the thera-
peutic range and then heparin was discontinued. The
patient was discharged home in a stable condition
with no complications. He remained well four months
later.
Figure 1 Pre-treatment transthoracic echocardiography (TTE).
(A) Left atrial thrombus adherent to mitral valve prosthesis and (B)
TTE showing (with arrows) the two leaflets of prosthetic mitral valve
(anterior leaflet mobile while posterior leaflet thrombosed and
immobile).
Figure 2 Transthoracic echocardiography (TTE). Appearance at 24 hours post treatment (A and B) showing (with arrows) both mitral leaflets
to be reasonably mobile: (A) in open position; (B) in closed position. (C and D) TEE appearance at 48 hours post treatment showing (with
arrows) fully mobile both mitral leaflets: (C) in open position; (D) in closed position.
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PVT is defined as any obstruction of prosthesis by non-
infective thrombotic material. It has an estimated inci-
dence of 0.03% - 4.3% per year [2] and is reported to
occur in 0.5% - 8% of the left-sided prosthetic valves
and in up to 20% of tricuspid prostheses [3,4]. The most
common cause of PVT is inadequate anticoagulant ther-
apy (in up to 82% of cases) [3]. Other pathogenic factors
include: mitral position of the prosthesis; type of pros-
thesis; atrial fibrillation; left atrial enlargement; ventricu-
lar dysfunction; and multiple valve replacements [5].
Diagnosis of prosthetic heart valve thrombosis is made
by a combination of clinical data (heart failure, absence
of prosthetic sounds, cardiogenic shock), fluoroscopic
examination (abnormal mobility of tilting disks) and
echocardiographic (both transthoracic and transoeso-
phageal ) abnormalities (high prosthetic gradient, reduc-
tion of effective valve orifice area, lack of disk mobility
and detection of thrombotic mass adherent to the pros-
thesis ) [3,6].
Management of PVT remains controversial. There are
currently no randomized controlled trials favoring sur-
gery over thrombolysis and vice versa. Surgery, in the
form of thrombectomy or valve replacement, remains
the treatment of choice but carries a significant mortal-
ity ranging from 4.7% to 20% [2,3,7]. Thrombolysis, on
the other hand, has emerged as an attractive alternative
with reported success rates in the region of 75%-88% for
PVT [2]. Our patient had stable hemodynamics which
gave us a window of opportunity to use thrombolysis
therapy. If this had been unsuccessful we would have
proceeded with surgery. In addition, the patient had
received his first MV replacement six months previously
and we felt that, by giving him a trial of thrombolysis,
we would have spared him the added burden of under-
going surgery twice in a short time period. The current
treatment algorithms suggested by some authors include
using thrombolysis for right sided PVT while using sur-
gery for left-sided PVT [8,9]. They also recommend
using thrombolytic therapy in left-sided PVT if surgery
is contraindicated or if the patient is critically ill [9].
Others have reported that patients in the New York
Heart Association functional classes I and II achieve the
best results with thrombolytic therapy with the lowest
incidence of peripheral embolism [10]. In our case, the
use of tenecteplase proved useful in a stable patient with
no increased risk. Following thrombolysis, he was placed
on oral anticoagulant only. We have not started him on
low-dose aspirin because there was no evidence of con-
comitant coronary artery disease and his thrombosed
valve was caused solely by his discontinuation of war-
farin. However, recent guidelines have suggested that in
such cases the use of low-dose aspirin, in addition to
oral anticoagulant, may decrease the chance of recur-
rence [11].
Thrombolytics reported in the literature are streptoki-
nase, urokinase and recombinant t-PA (alteplase) [5].
There are no studies comparing these different throm-
bolytic agents in PVT [3,7]. The most important compli-
cations of thrombolytic therapy are thromboembolic
events and cerebral hemorrhage. Thromboembolism is
more frequent in left-sided prosthesis with an incidence
of 9%-20%. Embolic complications occur in two forms:
peripheral embolism and cerebral. Cerebral embolism
has an overall incidence 3%-10% (more in the presence
of atrial fibrillation). Cerebral hemorrhage rates fluctuate
between 0%-3% [3,7]. Tenecteplase is a synthetically
engineered variant of alteplase designed to have
increased fibrin specificity, greater efficacy, increased
resistance to plasminogen activator inhibitor-1 (PAI-1)
and a longer half-life. It has been used extensively in
acute myocardial infarction (including in our institute)
but its use in PVT treatment has rarely been reported
[1,3]. One advantage of tenecteplase is that its dosing is
based on actual body weight which enhances both safety
and efficacy outcomes by avoiding wider fluctuations in
the drug plasma concentration. Compared to recombi-
nant t-PA (for example, alteplase), tenecteplase use
leads to lower rates of bleeding complications and a
decreased risk of cerebral hemorrhage among high risk
patients [12]. Tenecteplase, contrary to recombinant tis-
sue plasminogen activators, has been synthetically modi-
fied which in turn has important clinical applications.
The increased fibrin specificity theoretically enhances
the enzymatic activity at the clot and reduces systemic
fibrinolysis. Furthermore, the increased resistance to
PAI-1, an enzyme secreted by platelets that inhibit
thrombolytics, may enhance the efficacy of tenecteplase.
This drug proved useful in our case where successful
thrombolysis was achieved for mitral PVT with no
increased risk to the patient. We elected to use it in a
slow infusion rate rather than a bolus in order to poten-
tially reduce the risk of breaking up the thrombus into
large emboli and to potentially reduce the risk of cere-
bral bleed.
Conclusion
We present a rare case of mitral PVT which was suc-
cessfully treated with tenecteplase. Its use proved to be
useful with no extra risk to the patient.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompany-
ing images. A copy of the written consent is available
for review by the Editor-in-Chief of this journal.
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